CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy

Nature Medicine 2026 Open access

Read full text
Authors: Matthew Ho, Luca Paruzzo, Julia Han Noll, Federico Stella, Pooja Devi, Sonia Ndeupen, Yael A. Day, Gregory M. Chen, Ivan Cohen, Ángel Ramírez-Fernández, Adam Waxman, Shivani Kapur
+44 more Fang Chen, Rong Xu, Andrew Huff, Danuta Jarocha, Vrutti Patel, Audrey Bochi-Layec, Ranjani Ramasubramanian, S. Liu, Riemke Bouvier, Vitor B. de Souza, Heta Patel, Z. Li, Alberto Carturan, Peter Michener, Caitlin R. Hopkins, Owen Koucky, Janna Minehart, Alex Dimitri, Neel R. Nabar, Zainul S. Hasanali, Bryan T. Ciccarelli, Putzer Hung, Erik Williams, Robert L. Bartoszek, Maya Lavorando, Mohan Suyash, Vanessa Gonzalez, Patrizia Porazzi, Vijay Bhoj, Sokratis A. Apostolidis, Dan T. Vogl, David L. Porter, John Scholler, Caroline Diorio, Aoife M. Roche, J.K. Everett, Frederic D. Bushman, Katherine L. Nathanson, Stadtmauer Ea, Sandra P. Susanibar-Adaniya, Alfred L. Garfall, Marco Antonio Ruella, Adam D. Cohen, Joseph A. Fraietta
DOI: 10.1038/s41591-025-04121-8
Cited by: 14
References: 52

Fields of Study & Subjects

CAR-T cell therapy research Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses

Publication details

Journal / source
Nature Medicine
Publisher
Springer Science and Business Media LLC
Volume
32
Issue
2
Pages
702–716
Publication date
15 January 2026
Language
EN